IONETIX Hires Peter J. Burke as Vice President, Sales & Marketing
Healthcare and Nuclear Medicine Industry Veteran Will Provide Global Leadership to Position Company and Drive Growth
Lansing, MI – August 28, 2020 – IONETIX, the leading provider of Ammonia N-13 as a service to health systems, hospitals, cardiology and radiology practice groups in the United States, today announced that Peter J. Burke has joined the company as Vice President, Sales and Marketing, where he will lead the company’s sales and marketing efforts.
Mr. Burke brings with him over twenty years of sales, marketing, sales operations, and sales management experience primarily in the healthcare industry with a focus on nuclear medicine. Prior to joining IONETIX he served as Vice President, Sales and Marketing at IBA Moleculer/Zevacor where he drove steady growth, led the firm to national leadership position in IDEAS trials, designed and launched a bulk manufacturing program, and played a key role in the launch of a nationwide Centers of Innovation program.
Prior to that Mr. Burke served as Vice President Sales Operations and Inside Sales at Cardinal Health where he developed and deployed an inside sales team, led sales expansion into the Canada and Puerto Rico markets and led the successful deployment of salesforce.com. He held a number of other sales leadership roles at Cardinal Health and was honored as the company-wide leader in programmatic execution multiple times.
Prior to his tenure at Cardinal Health Mr. Burke was a Sales Manager at Syncor where he led a team of sales consultants and helped drive the company’s IDN strategy and implementation.
Mr. Burke is a Certified Lean Six Sigma Kaizen Leader and earned a Bachelor of Sciences from The Ohio State University.
IONETIX is a pioneering radio-pharmaceutical company providing Ammonia N-13 as a service to cardiac PET imaging providers (in the US). A growing number of key opinion leaders consider Ammonia N-13 the optimal tracer for myocardial perfusion imaging. IONETIX manufactures, installs, operates and manages cyclotrons and produces doses of Ammonia N-13, as ordered by physicians, at or near the imaging suite. The IONETIX cyclotron has a significantly smaller footprint than traditional machines and the unique Ammonia-as-a-service model makes using Ammonia N-13 easy and affordable for the cardiac imaging community.